Compression therapy for prevention of post-thrombotic syndrome.

Cochrane Database Syst Rev 2017 09 26;9:CD004174. Epub 2017 Sep 26.

Department of Dermatology, Huidcentrum Limburg, Reinaartsingel 50, Maastricht, Netherlands.

Background: Post-thrombotic syndrome (PTS) is a long-term complication of deep vein thrombosis (DVT) that is characterised by chronic pain, swelling, and skin changes in the affected limb. One of every three people with DVT will develop post-thrombotic complications within five years. Several non-pharmaceutical measures are used for prevention of post-thrombotic syndrome during the acute phase of DVT. These include elevation of the legs and compression therapy. Clinicians and guidelines differ in their assessment of the utility of compression therapy for treatment of DVT. This is an update of a review first published in 2003.

Objectives: To determine relative effectiveness and rate of complications when compression therapy is used in people with deep vein thrombosis (DVT) for prevention of post-thrombotic syndrome (PTS).

Search Methods: For this update, the Cochrane Vascular Information Specialist (CIS) searched the Cochrane Vascular Specialised Register (20 March 2017) and CENTRAL (2017, Issue 2). The CIS also searched trial registries for details of ongoing or unpublished studies.

Selection Criteria: We included randomised controlled trials (RCTs) and controlled clinical trials (CCTs) of compression therapy, such as bandaging and elastic stockings, in people with clinically confirmed DVT. The primary outcome was the occurrence of PTS.

Data Collection And Analysis: Two review authors (DK and EvL) identified and assessed titles and abstracts for relevance, and a third review author (DA) verified this assessment independently. Review authors imposed no restrictions on date or language of publications. Three review authors (DA, DK, EvL) used data extraction sheets to independently extract study data. We resolved disagreements by discussion.

Main Results: We identified 10 RCTs with a total of 2361 participants that evaluated compression therapy. The overall methodological quality of these trials was low. We used only five studies in meta-analysis owing to differences in intervention types and lack of data. Three studies compared elastic compression stockings (pressure of 30 to 40 mmHg at the ankle) versus no intervention. Two studies compared elastic compression stockings (pressure 20 to 40 mmHg) versus placebo stockings. Overall, use of elastic compression stockings led to a clinically significant reduction in the incidence of PTS (risk ratio (RR) 0.62, 95% confidence interval (CI) 0.38 to 1.01; P = 0.05; 1393 participants; 5 studies; low-quality evidence); no reduction in the incidence of severe PTS (RR 0.78, 95% CI 0.53 to 1.15; P = 0.21; 1224 participants; 4 studies; low-quality evidence); and no clear difference in DVT recurrence (RR 0.94, 95% CI 0.69 to 1.28; 1212 participants; 4 studies; P = 0.69; low-quality evidence). We did not pool data on the incidence of pulmonary embolism because this information was poorly reported, but we observed no differences between groups included in individual studies (low-quality evidence).Two studies evaluated effects of compression in the acute phase versus no compression treatment and found no differences in the incidence of PTS (RR 0.76, 95% CI 0.49 to 1.16; P = 0.2; 101 participants). One study reported that thigh-length stockings did not provide better protection against development of PTS than knee-length stockings (RR 0.92, 95% CI 0.66 to 1.28; P = 0.6; 267 participants). Another trial reported that wearing compression stockings for two years seemed to be superior to wearing them for one year in terms of PTS incidence.Two of the 10 included studies described patient satisfaction and quality of life (moderate-quality evidence), using different measurement systems. The first study showed significant improvement in well-being and DVT-related quality of life with compression treatment (P < 0.05) compared with bed rest, and the second study showed no differences in quality of life scores between compression and placebo groups. Four studies poorly reported side effects (low-quality evidence) that included itching, erythema, and other forms of allergic reaction and described no serious adverse events. Compliance with wearing of compression stockings was generally high but varied across studies.

Authors' Conclusions: Low-quality evidence suggests that elastic compression stockings may reduce the occurrence of PTS after DVT. We downgraded the quality of evidence owing to considerable heterogeneity between studies and lack of or unclear risk of blinding due to clinical assessment scores. No serious adverse effects occurred in these studies. Large randomised controlled trials are needed to confirm these findings because of current lack of high-quality evidence and considerable heterogeneity.

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD004174.pub3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6483721PMC
September 2017

Publication Analysis

Top Keywords

compression stockings
24
compression therapy
24
low-quality evidence
20
post-thrombotic syndrome
16
elastic compression
16
compression
16
studies low-quality
12
quality life
12
studies
12
participants studies
12
review authors
12
prevention post-thrombotic
12
stockings
10
considerable heterogeneity
8
randomised controlled
8
evidence
8
cis searched
8
evidence considerable
8
compared elastic
8
pressure mmhg
8

Similar Publications

Compression therapy for treating post-thrombotic syndrome.

Cochrane Database Syst Rev 2019 09 18;9:CD004177. Epub 2019 Sep 18.

Department of Dermatology, Huidcentrum Limburg, Maastricht, Netherlands.

Background: Post-thrombotic syndrome (PTS) is a long-term complication of deep vein thrombosis (DVT) characterised by chronic complaints such as oedema and skin changes including; venous ectasia, varicose veins, redness, eczema, hyperpigmentation, and in severe cases fibrosis of the subcutaneous adipose in the affected limb. These chronic complaints are the effects of venous outflow restriction that can cause symptoms such as heaviness, itching, pain, cramps, and paraesthesia. Twenty to fifty percent of people with DVT develop post-thrombotic complications. Read More

View Article and Full-Text PDF
September 2019

Rutosides for treatment of post-thrombotic syndrome.

Cochrane Database Syst Rev 2018 11 8;11:CD005625. Epub 2018 Nov 8.

Division of Epidemiology and Public Health, University of Nottingham, C120, Clinical Sciences Building - Ph2, City Hospital Campus, Hucknall Road, Nottingham, UK, NG5 1PB.

Background: Post-thrombotic syndrome (PTS) is a long-term complication of deep venous thrombosis (DVT) that is characterised by pain, swelling, and skin changes in the affected limb. One in three patients with DVT will develop post-thrombotic sequelae within five years. Rutosides are a group of compounds derived from horse chestnut (Aesculus hippocastanum), a traditional herbal remedy for treating oedema formation in chronic venous insufficiency (CVI). Read More

View Article and Full-Text PDF
November 2018

Non-pharmaceutical measures for prevention of post-thrombotic syndrome.

Cochrane Database Syst Rev 2004 (1):CD004174

Academic Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, Netherlands.

Background: Post-thrombotic syndrome (PTS) is a long-term complication of deep vein thrombosis (DVT) characterised by chronic pain, swelling and skin changes in the affected limb. One in every three patients with DVT will develop post-thrombotic complications within five years.

Objectives: To determine the relative effectiveness of, and the rate of complications using non-pharmaceutical interventions in patients with DVT in the prevention of PTS. Read More

View Article and Full-Text PDF
June 2004

Rutosides for treatment of post-thrombotic syndrome.

Cochrane Database Syst Rev 2015 Sep 16(9):CD005625. Epub 2015 Sep 16.

Centre for Population Health Sciences, University of Edinburgh, Medical Buildings, Teviot Place, Edinburgh, UK, EH8 9AG.

Background: Post-thrombotic syndrome (PTS) is a long-term complication of deep venous thrombosis (DVT) that is characterised by pain, swelling, and skin changes in the affected limb. One in three patients with DVT will develop post-thrombotic sequelae within five years. Rutosides are a group of compounds derived from horse chestnut (Aesculus hippocastanum), a traditional herbal remedy for treating oedema formation in chronic venous insufficiency (CVI). Read More

View Article and Full-Text PDF
September 2015